News stories about Curis (NASDAQ:CRIS) have trended somewhat positive on Monday, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Curis earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.1128416096909 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several research firms have recently weighed in on CRIS. ValuEngine cut Curis from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Zacks Investment Research upgraded Curis from a “sell” rating to a “hold” rating in a report on Monday, October 16th. BidaskClub upgraded Curis from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 17th. Finally, Guggenheim assumed coverage on Curis in a research note on Monday, October 23rd. They issued a “buy” rating and a $7.00 target price on the stock. Three research analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $6.50.

Curis (NASDAQ CRIS) traded up $0.08 during midday trading on Monday, reaching $0.87. The company’s stock had a trading volume of 5,265,900 shares, compared to its average volume of 744,818. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.24. Curis has a 12-month low of $0.79 and a 12-month high of $3.48.

Curis (NASDAQ:CRIS) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.02). The firm had revenue of $2.44 million during the quarter, compared to the consensus estimate of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. The company’s revenue was up 38.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.21) EPS. equities analysts expect that Curis will post -0.41 EPS for the current year.

In other news, CEO Ali Ph.D. Fattaey bought 50,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were purchased at an average price of $1.06 per share, for a total transaction of $53,000.00. Following the purchase, the chief executive officer now owns 115,890 shares of the company’s stock, valued at approximately $122,843.40. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 4.07% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Insider Buying and Selling by Quarter for Curis (NASDAQ:CRIS)

Receive News & Stock Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related stocks with our FREE daily email newsletter.